title: A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
abstract: Tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione (TIBO) derivatives (e.g., R82150) are potent, human immunodeficiency virus-1 (HIV-1)-specific, inhibitors of reverse transcriptase (RT) that are undergoing initial evaluation in clinical trials. Because HIV-1 has become resistant to other RT inhibitors, we investigated the potential for viral resistance to TIBO R82150 by serial in vitro passage of HIV-1IIIB in the presence of drug. R82150-resistant variants (> 100-fold increase in IC50) dominated the replicating virus population after only three or four passages. R82150-resistant virus was partially cross-resistant to other HIV-1-specific RT inhibitors, including nevirapine (approximately 10-fold increase in IC50) and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (approximately 3.5-fold increase) but remained susceptible to 2',3'-dideoxynucleosides and phosphonoformate. DNA sequencing of cloned resistant RT, combined with site-specific mutational analyses and construction of mutant recombinant proviruses, demonstrated that a single, conservative amino acid substitution (Leu100 to Ile) in HIV-1 RT is responsible for high level R82150 resistance and partial nevirapine resistance. These studies indicate that a subtle mutation in HIV-1 RT can dramatically affect viral susceptibility to an HIV-1-specific RT inhibitor. The clinical efficacy of TIBO derivatives and other HIV-1-specific RT inhibitors may be limited by the emergence of drug-resistant viral strains.
authors.affiliation: Department of Internal Medicine, University of Pittsburgh Medical Center, Pennsylvania.
authors.forename: J W
authors.initials: JW
authors.lastname: Mellors
authors.forename: G J
authors.initials: GJ
authors.lastname: Im
authors.forename: E
authors.initials: E
authors.lastname: Tramontano
authors.forename: S R
authors.initials: SR
authors.lastname: Winkler
authors.forename: D J
authors.initials: DJ
authors.lastname: Medina
authors.forename: G E
authors.initials: GE
authors.lastname: Dutschman
authors.forename: H Z
authors.initials: HZ
authors.lastname: Bazmi
authors.forename: G
authors.initials: G
authors.lastname: Piras
authors.forename: C J
authors.initials: CJ
authors.lastname: Gonzalez
authors.forename: Y C
authors.initials: YC
authors.lastname: Cheng
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D001483:Base Sequence; D001569:Benzodiazepines / Q000494:pharmacology*; D004351:Drug Resistance; D054303:HIV Reverse Transcriptase; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008969:Molecular Sequence Data; D009154:Mutation; D010641:Phenotype; D011533:Proviruses / Q000187:drug effects; D012194:RNA-Directed DNA Polymerase / Q000737:chemistry / Q000235:genetics; D018894:Reverse Transcriptase Inhibitors; D013329:Structure-Activity Relationship
chemical_list: D000998:Antiviral Agents; D007093:Imidazoles; D018894:Reverse Transcriptase Inhibitors; C062687:R 82150; D001569:Benzodiazepines; D054303:HIV Reverse Transcriptase; D012194:RNA-Directed DNA Polymerase